<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03112226</url>
  </required_header>
  <id_info>
    <org_study_id>17-0092</org_study_id>
    <nct_id>NCT03112226</nct_id>
  </id_info>
  <brief_title>Effects of Ovarian Hormone Suppression on Vascular and Cognitive Function</brief_title>
  <official_title>Effects of Ovarian Hormone Suppression on Vascular and Cognitive Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Complaints about memory and thinking are common in women as they go through menopause. The
      female hormone estrogen is important for both the health of both the brain and the blood
      vessels. In Alzheimer's disease there is damage to the blood vessels in the brain. This study
      will look at how the loss of the female hormone estrogen affects brain function and the
      health of blood vessels.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 2018</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Prefrontal cortex brain activation</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Changes in patterns of brain activation in the prefrontal cortex using functional magnetic resonance imaging (fMRI) during a task of working memory will be measured at baseline and 3 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Endothelial function</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Endothelial function will be measured using brachial artery flow-mediated dilation at baseline and 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Arterial stiffness</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Carotid artery compliance will be measured using ultrasound at baseline and 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Executive cognitive function</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Changes in executive cognitive function on a battery of neuropsychological tests will be measured at baseline and 3 months</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in Mitochondrial dysfunction</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>Measures of mitochondrial function including dynamics (fusion, fission), antioxidant defense and biogenesis will be measured in mitochondria isolated from peripheral blood mononuclear cells at baseline and 3 months.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cognitive Impairment</condition>
  <condition>Estrogen Deficiency</condition>
  <condition>Menopause</condition>
  <condition>Endothelial Dysfunction</condition>
  <condition>Vascular Stiffness</condition>
  <arm_group>
    <arm_group_label>GnRHant + E2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose of GnRH antagonist degarelix acetate for depot injection (80mg) Transdermal estradiol add-back; Climara patch, 0.075mg/day, weekly for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GnRHant + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of GnRH antagonist degarelix acetate for depot injection (80mg) Transdermal placebo patch, weekly for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>GnRHant + E2</intervention_name>
    <description>GnRH antagonist with estradiol add-back</description>
    <arm_group_label>GnRHant + E2</arm_group_label>
    <other_name>Degarelix acetate, Firmagon + Estradiol, Climara transdermal system</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>GnRHant + Placebo</intervention_name>
    <description>GnRH antagonist with placebo add-back</description>
    <arm_group_label>GnRHant + Placebo</arm_group_label>
    <other_name>Degarelix acetate, Firmagon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stages of Reproductive Aging Workshop (STRAW+10) peak or late reproductive stage (-4,
             -3b or -3a)

          -  Healthy based on medical history, physical examination and standard blood chemistries

          -  Normotensive (resting blood pressure &lt;140/90 mmHg)

          -  Normoglycemia (fasting glucose &lt;110mg/dl and hemoglobin A1c&lt;6.5%)

          -  Non-smoker (for at least 12 months)

        Exclusion Criteria:

          -  Serum Follical Stimulating Hormone (FSH) &gt;25mIU/mL measured during the first 5 days of
             the menstrual cycle

          -  Use of hormonal therapy within the past 3 months

          -  Use of antihypertensive or lipid-lowering medications

          -  Pregnant or lactating, or planning to become pregnant during the study period

          -  Known hypersensitivity to any of the study medications

          -  Abnormal vaginal bleeding

          -  History of venous thromboembolism or hormone-sensitive cancer

          -  History of neurologic disease or major psychiatric illness

          -  History of diagnosed learning disability or less than high-school education

          -  Contraindication to Magnetic Resonance Imaging (MRI) scanning

          -  Depression (Center for Epidemiological Studies - Depression (CESD) score &gt;16)

          -  Significant cognitive impairment (Mini Mental State Examination (MMSE) score &lt;27)

          -  Severe osteopenia or osteoporosis (proximal femur or lumbar spine T-score &lt; -2.0)

          -  Body Mass Index (BMI) &gt;40kg/m2
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kerry L Hildreth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kerry L Hildreth, MD</last_name>
    <phone>303-724-1927</phone>
    <email>kerry.hildreth@ucdenver.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerry L Hildreth, MD</last_name>
      <phone>303-724-1927</phone>
      <email>kerry.hildreth@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Kerrie L Moreau, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jim Grigsby, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert S Schwartz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wendy M Kohrt, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kerry L Hildreth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Boulder Intermountain Neuroimaging Consortium</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie T Banich, PhD</last_name>
      <phone>303-492-6655</phone>
      <email>marie.banich@colorado.edu</email>
    </contact>
    <investigator>
      <last_name>Marie T Banich, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2017</study_first_submitted>
  <study_first_submitted_qc>April 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2017</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cognitive impairment</keyword>
  <keyword>menopause</keyword>
  <keyword>estrogen</keyword>
  <keyword>functional MRI</keyword>
  <keyword>executive function</keyword>
  <keyword>endothelial function</keyword>
  <keyword>arterial stiffness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>LHRH, N-acetyl-(4-chlorophenylalanyl)(1)-(4-chlorophenylalanyl)(2)-tryptophyl(3)-arginyl(6)-alanine(10)-</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

